Tissue transglutaminase, inflammation, and cancer: How intimate is the relationship?

Amino Acids

Volumn 44, Issue 1, 2013, Pages 81-88

  Kumar, Santosh ^a   Mehta, Kapil ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer stem cells; Chemoresistance; EMT; Inflammation; Metastasis; Transglutaminase 2

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TISSUE PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TISSUE PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2 INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL SUBPOPULATION; CELL TRANSFORMATION; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DESIGN; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; METASTASIS; METASTASIS POTENTIAL; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

AMINO ACID SEQUENCE; ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MOLECULAR SEQUENCE DATA; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSGLUTAMINASES;

EID: 84871994461     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-011-1139-0     Document Type: Review

References (60)

1. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545
2. Bertout J, Thomas-Tikhonenko A (2006) Infection and neoplastic growth 101: the required reading for microbial pathogens aspiring to cause cancer. Cancer Treat Res 130:167-197
3. Clarke DD, Mycek MJ, Neidle A, Waelsch H (1957) The incorporation of amines into proteins. Arch Biochem Biophys 79:338-354
4. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D (1997) Identification of tissue transglutaminase as the autoantigen of coeliac disease. Nat Med 3:797-801
5. Dubin PJ, McAllister F, Kolls JK (2007) Is cystic fibrosis a TH17 disease? Inflamm Res 56:221-227
6. Elli L, Bergamini CM, Bardella MT, Schuppan D (2009) Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis 41:541-550
7. Facchiano F, Facchiano A, Facchiano AM (2006) The role of transglutaminase-2 and its substrates in human diseases. Front Biosci 11:1758-1773
8. Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876-885
9. Fok JY, Ekmekcioglu S, Mehta K (2006) Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 5:1493-1503
10. Frese-Schaper M, Schardt JA, Sakai T, Carboni GL, Schmid RA, Frese S (2010) Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5. FEBS Lett 584:2867-2871
11. Grenard P, Bresson-Hadni S, El Alaoui S, Chevallier M, Vuitton DA, Ricard-Blum S (2001) Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis. J Hepatol 35:367-375
12. Griffin M, Casadio R, Bergamini CM (2002) Transglutaminases: nature's biological glues. Biochem J 368:377-396
13. Grivennikov S, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883-899
14. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK (2008) Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 68:5849-5858
15. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63:8614-8622
16. Iismaa SE, Mearns BM, Lorand L, Graham RM (2009) Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 89:991-1023
17. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grünert S (2002) Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 156:299-313
18. Jeanes A, Gottardi CJ, Yap AS (2008) Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27:6920-6929
19. Jiang D, Ying W, Lu Y, Wan J, Zhai Y, Liu W, Zhu Y, Qiu Z, Qian X, He F (2003) Identification of metastasis associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis. Proteomics 3:724-737
20. Johnson TS, Griffin M, Thomas GL, Skill J, Cox A, Yang B, Nicholas B, Birckbichler PJ, Muchaneta-Kubara C, Meguid El Nahas A (1997) The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest 99:2950-2960
21. Johnson K, Hashimoto S, Lotz M, Pritzker K, Terkeltaub R (2001) Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am J Pathol 159:149-163
22. Johnson TS, EI-Koraie AF, Skill NJ, Baddour NM, EI Nahas AM, Njloma M, Adam AG, Griffin M (2003) Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 14:2052-2062
23. Kalluri R (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119:1417-1419
24. Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776-1784
25. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392-401
26. Kiemer AK, Takeuchi K, Quinlan MP (2001) Identification of genes involved in epithelial-mesenchymal transition and tumor progression. Oncogene 20:6679-6688
27. Kim SY (2006) Transglutaminase 2 in inflammation. Front Biosci 11:3026-3035
28. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K (2010) Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 5:e13390
29. Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K (2011) Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One 6:e20701
30. Kuncio GS, Tsyganskaya M, Zhu J, Liu S-L, Nagy L, Thomazy V, Davies PJ, Zern MA (1998) TNF alpha modulates expression of the tissue transglutaminase gene in liver cells. Am J Physiol 274:G240-G245
31. Lee KN, Birckbichler PJ, Patterson MK Jr (1989) GTP hydrolysis by guinea pig liver transglutaminase. Biochem Biophys Res Commun 162:1370-1375
32. Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, Kim SY (2004) Transglutaminase 2 induces nuclear factor-κB activation via a novel pathway in BV-2 microglia. J Biol Chem 279:53725-53735
33. Lesort M, Tucholski J, Miller ML, Johnson GV (2000) Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog Neurobiol 61:439-463
34. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139:891-906
35. Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D'Apolito M, Pettoello-Mantovani M, Guido S, Ciacci C, Cimmino M, Cexus ON, Londei M, Quaratino S (2008) Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J Immunol 180:7697-7705
36. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K (2007) Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 26:2459-2470
37. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal BB, Mehta K (2006) Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-κB in cancer cells: delineation of a novel pathway. Cancer Res 66:8788-8795
38. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer related inflammation. Nature 454:436-444
39. Mehta K, Eckert R (2005) Transglutaminases - family of enzymes with diverse functions. Prog Exp Tumor Res 38:1-247
40. Mehta K, Fok J, Miller FR, Koul D, Sahin AA (2004) Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10:8068-8076
41. Mehta K, Kumar A, Kim HI (2010) Transglutaminase 2: A multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol 80:1921-1929
42. Nakaoka H, Perez DM, Baek KJ, Das T, Husain A, Misono K, Im MJ, Graham RM (1994) Gh: a GTPbinding protein with transglutaminase activity and receptor signaling function. Science 264:1593-1596
43. Osika E, Cavaillon JM, Chadelat K, Boule M, Fitting C, Tournier G, Clement A (1999) Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Eur Respir J 14:339-346
44. Park KS, Kim HK, Lee JH, Choi YB, Park SY, Yang SH, Kim SY, Hong KM (2010) Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol 136:493-502
45. Pinkas DM, Strop P, Brunger AT, Khosla C (2007) Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 5:e327
46. Quan G, Choi JY, Lee DS, Lee SC (2005) TGF-beta1 upregulates transglutaminase 2 and fibronectin in dermal fibroblasts: a possible mechanism for the stabilization of tissue inflammation. Arch Dermatol Res 297:84-90
47. Richards RJ, Masek LC, Brown RF (1991) Biochemical and cellular mechanisms of pulmonary fibrosis. Toxicol Pathol 19:526-539
48. Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, Bigsby RM, Nakshatri H, Matei D (2009) Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 69:9192-9201
49. Shweke N, Boulos N, Jouanneau C, Vandermeersch S, Melino G, Dussaule JC, Chatziantoniou C, Ronco P, Boffa JJ (2008) Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol 173:631-642
50. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741-4751
51. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454
52. Verderio EA, Johnson T, Griffin M (2004) Tissue transglutaminase in normal and abnormal wound healing: review article. Amino Acids 26:387-404
53. Verderio EA, Johnson TS, Griffin M (2005) Transglutaminases in wound healing and inflammation. Prog Exp Tumor Res 38:89-114
54. Verma A, Mehta K (2007a) Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 10:144-151
55. Verma A, Mehta K (2007b) Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets 7:559-565
56. Verma A, Wang H, Manavathi B, Fok JY, Mann AP, Kumar R, Mehta K (2006) Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 66:10525-10533
57. Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K (2008) Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 14:2476-2483
58. Vincent-Salomon A, Thiery JP (2003) Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 5:101-106
59. Yuan L, Choi K, Khosla C, Zheng X, Higashikubo R, Chicoine MR, Rich KM (2005) Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther 4:1293-1302
60. Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, Rich KM (2007) Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26:2563-2573